Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시) (제2회차 CB)
Regulatory Filings
2026-04-30 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 70% confidence The document is a corporate disclosure of a single sales and supply contract with Pfizer Inc. It details contract terms, amounts, and conditions. It is not a financial report (Annual, Interim, Earnings, etc.), not a governance or management change notice, not a share issuance or dividend announcement, nor an M&A or financing update. It’s essentially a regulatory announcement of a contractual agreement, which falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-16 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 91% confidence The document is a Korean Major Items Report filed with the Financial Supervisory Service and Korea Exchange, detailing the decision to issue convertible bonds (사모 전환사채 발행결정), including full terms of the bond, interest, conversion, put and call options, investor list and amounts. This is a financing activity announcement updating the company’s capital structure and fund‐raising arrangement. It is not merely an announcement of an upcoming report, but the actual financing decision and terms. Consequently, it fits the “Capital/Financing Update (CAP)” category.
2026-04-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is an official announcement of the results of the company’s regular general meeting (Annual General Meeting), including voting outcomes on each resolution and details of director appointments. This matches the category ‘Declaration of Voting Results & Voting Rights Announcements’. It is not the meeting materials or a full report but specifically the vote results.
2026-03-30 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 92% confidence The document is a formal notification of the appointment, reappointment, dismissal, or mid‐term retirement of an outside director (“사외이사 변경”). It is an announcement of changes in the company’s board of directors, matching the definition of Board/Management Information (MANG).
2026-03-30 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the 12th fiscal year (2025), covering company overview, history, management, capital structure, and detailed business operations. It contains financial data, management discussion, and analysis. This is the standard Korean regulatory filing equivalent to a 10-K. FY 2025
2026-03-20 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.